Appearance of islet cell autoantibodies after clinical diagnosis of diabetes mellitus
(1999) In Autoimmunity 29(1). p.57-63- Abstract
Islet cell antibodies (ICA) and glutamic acid decarboxylase antibodies (GAD65Ab) are often present at diagnosis of insulin dependent diabetes mellitus (type I diabetes) and are supposed to decline in level and frequency during the first years of disease. We have analysed ICA and GAD65Ab at onset and after one gear in 395 population based randomly selected 15-34 year old patients newly diagnosed with diabetes mellitus, to study how these autoantibodies persist, disappear and appear and their relation to C-peptide levels. Of the 395 samples 212 (54%) were positive for ICA, 250 (63%) were positive for GAD65Ab and 170 (43%) were positive for both. At follow up after one year, 27/183 (15%) of the ICA negative patients and 25/145 (17%) of the... (More)
Islet cell antibodies (ICA) and glutamic acid decarboxylase antibodies (GAD65Ab) are often present at diagnosis of insulin dependent diabetes mellitus (type I diabetes) and are supposed to decline in level and frequency during the first years of disease. We have analysed ICA and GAD65Ab at onset and after one gear in 395 population based randomly selected 15-34 year old patients newly diagnosed with diabetes mellitus, to study how these autoantibodies persist, disappear and appear and their relation to C-peptide levels. Of the 395 samples 212 (54%) were positive for ICA, 250 (63%) were positive for GAD65Ab and 170 (43%) were positive for both. At follow up after one year, 27/183 (15%) of the ICA negative patients and 25/145 (17%) of the GAD65Ab negative patients had converted to positivity. Among the 103 patients negative for both ICA and GAD65Ab, 16 turned positive for one or both antibodies after one year. Patients converting to positivity for one or the other antibody after one year, had lower C-peptide levels after one year than patients who initially were and remained negative, supporting the hypothesis that these patients have a genuine type I diabetes. In conclusion, newly diagnosed patients may be negative for autoantibodies at diagnosis but develop these antibodies later on during the disease.
(Less)
- author
- organization
- publishing date
- 1999-01-01
- type
- Contribution to journal
- publication status
- published
- keywords
- Autoimmunity, C-peptide, GAD65 antibodies, Islet cell antibodies
- in
- Autoimmunity
- volume
- 29
- issue
- 1
- pages
- 7 pages
- publisher
- Taylor & Francis
- external identifiers
-
- scopus:0033010230
- pmid:10052686
- ISSN
- 0891-6934
- DOI
- 10.3109/08916939908995973
- language
- English
- LU publication?
- yes
- id
- 5f1f2b18-4625-48ab-a229-7ae50acefa04
- date added to LUP
- 2019-06-30 23:29:45
- date last changed
- 2024-10-02 08:31:42
@article{5f1f2b18-4625-48ab-a229-7ae50acefa04, abstract = {{<p>Islet cell antibodies (ICA) and glutamic acid decarboxylase antibodies (GAD65Ab) are often present at diagnosis of insulin dependent diabetes mellitus (type I diabetes) and are supposed to decline in level and frequency during the first years of disease. We have analysed ICA and GAD65Ab at onset and after one gear in 395 population based randomly selected 15-34 year old patients newly diagnosed with diabetes mellitus, to study how these autoantibodies persist, disappear and appear and their relation to C-peptide levels. Of the 395 samples 212 (54%) were positive for ICA, 250 (63%) were positive for GAD65Ab and 170 (43%) were positive for both. At follow up after one year, 27/183 (15%) of the ICA negative patients and 25/145 (17%) of the GAD65Ab negative patients had converted to positivity. Among the 103 patients negative for both ICA and GAD65Ab, 16 turned positive for one or both antibodies after one year. Patients converting to positivity for one or the other antibody after one year, had lower C-peptide levels after one year than patients who initially were and remained negative, supporting the hypothesis that these patients have a genuine type I diabetes. In conclusion, newly diagnosed patients may be negative for autoantibodies at diagnosis but develop these antibodies later on during the disease.</p>}}, author = {{Landin-Olsson, Mona and Arnqvist, Hans J. and Blohmé, Göran and Littorin, Bengt and Lithner, Folke and Nyström, Lennarth and Scherstén, Bengt and Sundkvist, Göran and Wibell, Lars and Östman, Jan and Lernmark, Åke}}, issn = {{0891-6934}}, keywords = {{Autoimmunity; C-peptide; GAD65 antibodies; Islet cell antibodies}}, language = {{eng}}, month = {{01}}, number = {{1}}, pages = {{57--63}}, publisher = {{Taylor & Francis}}, series = {{Autoimmunity}}, title = {{Appearance of islet cell autoantibodies after clinical diagnosis of diabetes mellitus}}, url = {{http://dx.doi.org/10.3109/08916939908995973}}, doi = {{10.3109/08916939908995973}}, volume = {{29}}, year = {{1999}}, }